Homocysteine, a sulfur-containing amino acid, acts as both an agonist and partial antagonist at the N-methyl-D-aspartate (NMDA) receptor. At the glutamate binding site, it functions as an agonist, while at the glycine coagonist site, it acts as a partial antagonist. Under normal physiological conditions, homocysteine levels are low, and its neurotoxic effects are minimal. However, in pathological conditions such as stroke or head trauma, where glycine levels are elevated, homocysteine's agonist activity at the NMDA receptor becomes dominant, leading to excessive calcium influx and reactive oxygen generation, which causes neuronal damage. In children with homocystinuria, homocysteine levels are severely elevated, reaching millimolar concentrations, which can lead to neurotoxicity. In adults, modest elevations of homocysteine (tens of micromolar) are associated with increased risk of vascular disease and stroke. Homocysteine's neurotoxicity is mediated through overstimulation of NMDA receptors, contributing to the pathogenesis of both homocystinuria and hyperhomocysteinemia. The study shows that homocysteine can cause direct neurotoxicity by activating NMDA receptors. Excessive stimulation of these receptors leads to brain damage in focal ischemia. Homocysteine's neurotoxic effects are exacerbated in the presence of elevated glycine levels, which are common in conditions like stroke and head trauma. The study also demonstrates that homocysteine can act as an excitotoxin, contributing to neuronal damage through NMDA receptor overactivation. The findings suggest that therapeutic approaches targeting NMDA receptor down-regulation or using NMDA receptor antagonists may be beneficial in treating hyperhomocysteinemia. Additionally, drugs that protect against NMDA receptor-mediated neurotoxicity could be useful in preventing neuronal damage in stroke patients. The study also highlights the potential role of reactive oxygen species in homocysteine-induced neurotoxicity. Overall, the study provides important insights into the mechanisms by which homocysteine contributes to neurotoxicity and vascular disease.Homocysteine, a sulfur-containing amino acid, acts as both an agonist and partial antagonist at the N-methyl-D-aspartate (NMDA) receptor. At the glutamate binding site, it functions as an agonist, while at the glycine coagonist site, it acts as a partial antagonist. Under normal physiological conditions, homocysteine levels are low, and its neurotoxic effects are minimal. However, in pathological conditions such as stroke or head trauma, where glycine levels are elevated, homocysteine's agonist activity at the NMDA receptor becomes dominant, leading to excessive calcium influx and reactive oxygen generation, which causes neuronal damage. In children with homocystinuria, homocysteine levels are severely elevated, reaching millimolar concentrations, which can lead to neurotoxicity. In adults, modest elevations of homocysteine (tens of micromolar) are associated with increased risk of vascular disease and stroke. Homocysteine's neurotoxicity is mediated through overstimulation of NMDA receptors, contributing to the pathogenesis of both homocystinuria and hyperhomocysteinemia. The study shows that homocysteine can cause direct neurotoxicity by activating NMDA receptors. Excessive stimulation of these receptors leads to brain damage in focal ischemia. Homocysteine's neurotoxic effects are exacerbated in the presence of elevated glycine levels, which are common in conditions like stroke and head trauma. The study also demonstrates that homocysteine can act as an excitotoxin, contributing to neuronal damage through NMDA receptor overactivation. The findings suggest that therapeutic approaches targeting NMDA receptor down-regulation or using NMDA receptor antagonists may be beneficial in treating hyperhomocysteinemia. Additionally, drugs that protect against NMDA receptor-mediated neurotoxicity could be useful in preventing neuronal damage in stroke patients. The study also highlights the potential role of reactive oxygen species in homocysteine-induced neurotoxicity. Overall, the study provides important insights into the mechanisms by which homocysteine contributes to neurotoxicity and vascular disease.